Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (191-200 of 228) with videos related to

Pageof 23
Sort By:
Breast Care (Basel, Switzerland)|February 22, 2024
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR StudyNadia Harbeck, Denise Wrobel, Matthias Zaiss, et al.
Virchows Archiv : an International Journal of Pathology|May 9, 2020
Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimensKristina A Tendl-Schulz, Fabian Rössler, Philipp Wimmer, et al.
NPJ Breast Cancer|April 8, 2026
Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 TrialDaniel Egle, Dominik Hlauschek, Simon Peter Gampenrieder, et al.
Breast (Edinburgh, Scotland)|November 6, 2025
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34Stephanie Kacerovsky-Strobl, Christine Deutschmann, Dominik Hlauschek, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohortLuca Visani, Ivica Ratosa, Rupert Bartsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study GroupPeter C Dubsky, Raimund Jakesz, Brigitte Mlineritsch, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialThorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Nature Medicine|September 13, 2024
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNadia Harbeck, Eva Ciruelos, Guy Jerusalem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor ResponseQing Zhou, Simon P Gampenrieder, Sophie Frantal, et al.
Nature Medicine|December 9, 2024
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNadia Harbeck, Eva Ciruelos, Guy Jerusalem, et al.
Pageof 23

Showing results (191-200 of 228) with videos related to

Sort By:
Pageof 23
Breast Care (Basel, Switzerland)|February 22, 2024
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR StudyNadia Harbeck, Denise Wrobel, Matthias Zaiss, et al.
Virchows Archiv : an International Journal of Pathology|May 9, 2020
Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimensKristina A Tendl-Schulz, Fabian Rössler, Philipp Wimmer, et al.
NPJ Breast Cancer|April 8, 2026
Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 TrialDaniel Egle, Dominik Hlauschek, Simon Peter Gampenrieder, et al.
Breast (Edinburgh, Scotland)|November 6, 2025
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34Stephanie Kacerovsky-Strobl, Christine Deutschmann, Dominik Hlauschek, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
Concomitant radiation therapy and trastuzumab deruxtecan in metastatic breast cancer: feasibility, safety, and outcomes from a real-life multicentre international cohortLuca Visani, Ivica Ratosa, Rupert Bartsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study GroupPeter C Dubsky, Raimund Jakesz, Brigitte Mlineritsch, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialThorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Nature Medicine|September 13, 2024
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNadia Harbeck, Eva Ciruelos, Guy Jerusalem, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2021
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor ResponseQing Zhou, Simon P Gampenrieder, Sophie Frantal, et al.
Nature Medicine|December 9, 2024
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNadia Harbeck, Eva Ciruelos, Guy Jerusalem, et al.
Pageof 23